This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Tumor necrosis factor receptor 1 (TNFRSF1A; TNFR1; CD120a)	<p>A study in mice suggests decreasing TNFRSF1A could improve the safety of tumor necrosis factor (TNF)-based cancer treatments. In mouse models for cancer, an anti-TNFRSF1A mAb decreased the frequency of lethal toxicity compared with control antibody but preserved the antitumor effect of TNF treatment. In transgenic mice expressing human <i>TNFRSF1A</i>, a pegylated anti-TNFRSF1A Fab fragment prevented acute TNF-mediated lethality but enabled full TNF-mediated tumor regression. Next steps include assessing heterogeneity of TNFRSF1A levels in human patients and confirming safety and efficiency of the antibody in other solid tumors, including in animal models for spontaneous tumor development.</p> <p>SciBX 6(22); doi:10.1038/scibx.2013.543 Published online June 6, 2013</p>	Patent status not applicable; models and tools available for licensing	<p>Van Hauwermeiren, F. <i>et al.</i> <i>J. Clin. Invest.</i>; published online May 15, 2013;doi:10.1172/JCI65624 Contact: George Kollias, Biomedical Sciences Research Center Alexander Fleming, Vari, Greece e-mail: kollias@fleming.gr Contact: Claude Libert, Flancers Institute for Biotechnology and Ghent University, Ghent, Belgium e-mail: claude.libert@ugent.be</p>